Two Models of Health, One Executive, and a Divided Industry

There is a particular anxiety that settles over a high-performing executive at midlife—the sense that the energy that once came easily now requires effort, that the edge has dulled, that something has changed beneath the surface. For decades, the response to that anxiety has been a visit to a doctor, a prescription, and a follow-up in six months. A newer industry is offering something different: performance coaches who promise to rebuild capacity rather than manage symptoms, and a debate about who should be trusted with the health of the people who run things.

The trend is visible in the numbers. The Australian Financial Review reports on C-suite executives paying upward of $5,000 a month for "biological coaching"—comprehensive health testing and performance optimization that sits outside the traditional medical model . One executive, a 51-year-old chief people officer, attributed her brain fog and anxiety to perimenopause until a genetic test revealed she had trouble absorbing vitamin B12. After injections, she said, "it was, 'Oh, that's what it's like to feel normal again'" .

The divide between doctors and coaches is not merely about money. Former ER physician Dr. Sean O'Mara, now a critic of the traditional model, argues that medicine is built for acute crisis care, not proactive performance optimization. When a 48-year-old executive presents with high cholesterol, the default response is a prescription pad—statins, blood pressure medication, a follow-up in six months. Very few physicians audit nutrition, evaluate physical training, or address the lifestyle drivers of metabolic decay . He calls this the "pedestal problem"—society's conditioning to view doctors as the sole authority on health, to the exclusion of coaches who drive behavioral change.

Doctors, for their part, have reason to be cautious. The performance coaching industry is largely unregulated, and the line between optimization and over-treatment is not always clear. The tests that coaches order—genetic panels, advanced biomarkers, comprehensive hormone profiles—may produce data that is actionable, or may produce anxiety without clear benefit. The executive who learns she has a genetic variant affecting vitamin absorption has gained something useful. The executive who learns he has a variant of uncertain significance has gained a question he cannot answer.

What the debate often obscures is that both models are addressing real gaps. Traditional medicine saves lives in emergencies and manages chronic disease with tools that have been rigorously tested. Performance coaching addresses the space between pathology and optimal function—the space where many executives live, feeling neither sick nor well. The question is not which model is superior but whether they can be integrated, and whether the people who seek help can distinguish between evidence-based guidance and expensive placebo.

For now, the market is making its choice. Executives who can afford it are paying for the integration, and the coaches who provide it are building a parallel system alongside the one that doctors have long dominated. Whether that system will be held to the same standards of evidence and accountability remains to be seen.

AI Image Disclaimer: The visuals in this report were produced using artificial intelligence and serve an illustrative purpose only.

Sources: Australian Financial Review, LinkedIn